S&P 500 Futures
(-0.13%) 5 246.00 points

Dow Jones Futures
(0.02%) 38 238 points

Nasdaq Futures
(-0.28%) 18 555 points

Oil
(0.00%) $77.91

Gas
(-0.97%) $2.55

Gold
(-0.10%) $2 364.20

Silver
(-0.46%) $31.39

Platinum
(-0.47%) $1 033.10

USD/EUR
(-0.04%) $0.923

USD/NOK
(-0.11%) $10.53

USD/GBP
(0.17%) $0.787

USD/RUB
(0.08%) $90.34

Realtime updates for Ono Pharmaceutical Co., [4528.T]

Exchange: JPX Sector: Healthcare Industry: Drug Manufacturers—General

Last Updated31 May 2024 @ 02:15

25% discount on Stockinvest.us - Use code: Podcast

3.41% ¥ 2 275.00

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 02:15):

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors...

Stats
Today's Volume	9.82M
Average Volume	2.06M
Market Cap	1 068.45B
EPS	¥37.53 ( 2024-05-10 )
Next earnings date	( ¥61.83 ) 2024-07-28
Last Dividend	¥37.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	8.53
ATR14	¥1.435 (0.06%)

Volume Correlation

Long: 0.51 (weak)

Short: 0.77 (moderate)

Signal:(61.985) Neutral

Ono Pharmaceutical Co., Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ono Pharmaceutical Co., Correlation - Currency/Commodity

-0.56
( weak negative )

-0.13
( neutral )

-0.54
( weak negative )

-0.43
( neutral )

0.02
( neutral )

-0.37
( neutral )

Ono Pharmaceutical Co., Financials

Annual	2023
Revenue:	¥502.67B
Gross Profit:	¥375.55B (74.71 %)
EPS:	¥266.62

FY	2023
Revenue:	¥502.67B
Gross Profit:	¥375.55B (74.71 %)
EPS:	¥266.62

FY	2022
Revenue:	¥447.19B
Gross Profit:	¥337.13B (75.39 %)
EPS:	¥230.85

FY	2022
Revenue:	¥361.36B
Gross Profit:	¥267.85B (74.12 %)
EPS:	¥162.19

Financial Reports:

No articles found.

Ono Pharmaceutical Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥33.00 (N/A)	¥0 (N/A)	¥37.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Ono Pharmaceutical Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.63 - Increase likely (52.51%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥6.80	2001-03-27
Last Dividend	¥37.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	41	--
Total Paid Out	¥671.50	--
Avg. Dividend % Per Year	0.00%	--
Score	4.4	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.63
Div. Directional Score	9.98	--

Next Divdend (Est)
(2024-10-14)

¥0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

4.40

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
7979.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0	0.00%
7213.T	Ex Dividend Knight	2024-03-28	Annually	0	0.00%
6459.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0	0.00%
5471.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0	0.00%
4461.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0	0.00%
3641.T	Ex Dividend Junior	2024-03-28	Annually	0	0.00%
2897.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0	0.00%
1716.T	Ex Dividend Knight	2024-06-27	Annually	0	0.00%
9763.T	Ex Dividend Junior	2023-09-28	Annually	0	0.00%
8842.T	Ex Dividend Knight	2024-01-30	Semi-Annually	0	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.255	1.500	4.91	7.36	[0 - 0.5]
returnOnAssetsTTM	0.140	1.200	5.33	6.40	[0 - 0.3]
returnOnEquityTTM	0.164	1.500	9.29	10.00	[0.1 - 1]
payoutRatioTTM	0.291	-1.000	7.09	-7.09	[0 - 1]
currentRatioTTM	3.99	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.29	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.603	1.500	2.20	3.31	[0.2 - 2]
debtRatioTTM	0.00970	-1.500	9.84	-10.00	[0 - 0.6]
interestCoverageTTM	119.29	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	234.16	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	190.09	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0112	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.747	1.000	0.882	0.882	[0.2 - 0.8]
operatingProfitMarginTTM	0.324	1.000	5.51	5.51	[0.1 - 0.6]
cashFlowToDebtRatioTTM	12.49	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.550	0.800	9.67	7.73	[0.5 - 2]
Total Score				12.33

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	8.35	1.000	9.26	0	[1 - 100]
returnOnEquityTTM	0.164	2.50	9.54	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	190.09	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	3.54	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	234.16	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.291	1.500	7.09	-7.09	[0 - 1]
pegRatioTTM	0.568	1.500	9.55	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.220	1.000	7.00	0	[0.1 - 0.5]
Total Score				7.63

Ono Pharmaceutical Co., Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Ono Pharmaceutical Co.,

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.